Search research articles
Contact Us
Filters
Showing results (31-40 of 115) with videos related to
Page
of 12
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
November 27, 2007
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial
Morten Sorensen, Ulrik Lassen, Torben Palshof, et al.
Cancer Chemotherapy and Pharmacology
|
October 24, 2003
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent
Patricia E Schroeder, Kenneth Francis Hofland, Peter Buhl Jensen, et al.
Thescientificworldjournal
|
September 14, 2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
Ingrid H Olsen, Jens B Sørensen, Birgitte Federspiel, et al.
Toxicology
|
January 19, 2010
A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage
Annemette V Thougaard, Seppo W Langer, Bo Hainau, et al.
Diagnostics (Basel, Switzerland)
|
May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine Neoplasms
Esben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 30, 2016
Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients
Camilla B Johnbeck, Ulrich Knigge, Seppo W Langer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 17, 2020
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial
Morten Quist, Seppo W Langer, Christian Lillelund, et al.
BMC Cancer
|
January 12, 2020
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
Kirstine Nielsen, Tina Binderup, Seppo W Langer, et al.
Current Oncology Reports
|
January 3, 2024
Appendiceal Neuroendocrine Neoplasms: an Update for 2023
Pernille Holmager, Seppo W Langer, Andreas Kjaer, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 115) with videos related to
Sort By:
Page
of 12
Lung Cancer (Amsterdam, Netherlands)
|
November 27, 2007
Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial
Morten Sorensen, Ulrik Lassen, Torben Palshof, et al.
Cancer Chemotherapy and Pharmacology
|
October 24, 2003
Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent
Patricia E Schroeder, Kenneth Francis Hofland, Peter Buhl Jensen, et al.
Thescientificworldjournal
|
September 14, 2012
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
Ingrid H Olsen, Jens B Sørensen, Birgitte Federspiel, et al.
Toxicology
|
January 19, 2010
A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage
Annemette V Thougaard, Seppo W Langer, Bo Hainau, et al.
Diagnostics (Basel, Switzerland)
|
May 11, 2024
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu/<sup>225</sup>AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 18, 2022
Prospective Phase II Trial of [<sup>68</sup>Ga]Ga-NODAGA-E[c(RGDyK)]<sub>2</sub> PET/CT Imaging of Integrin α<sub>v</sub>β<sub>3</sub> for Prognostication in Patients with Neuroendocrine Neoplasms
Esben Andreas Carlsen, Mathias Loft, Annika Loft, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 30, 2016
Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients
Camilla B Johnbeck, Ulrich Knigge, Seppo W Langer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 17, 2020
Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial
Morten Quist, Seppo W Langer, Christian Lillelund, et al.
BMC Cancer
|
January 12, 2020
P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms
Kirstine Nielsen, Tina Binderup, Seppo W Langer, et al.
Current Oncology Reports
|
January 3, 2024
Appendiceal Neuroendocrine Neoplasms: an Update for 2023
Pernille Holmager, Seppo W Langer, Andreas Kjaer, et al.
Page
of 12